Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSITE DE GENEVE has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, including GALSTER, SAMUEL LEONARD, who is the busiest examiner with 1 pending case. This distribution shows that each examiner is currently handling a portion of the 2 pending office actions for the portfolio.
The prosecution is concentrated within 1 distinct art unit, even though 2 distinct examiners are involved. This indicates that while the technical subject matter is contained in a single unit, the company is interacting with multiple officials. With 2 pending office actions total, the strategy for this portfolio requires managing two separate examiner relationships within the same technical group. Practitioners should focus on the specific norms of the 1 distinct art unit while addressing the individual perspectives of the 2 distinct examiners assigned to these cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761626 | CELLULAR SUBSTITUTES AND METHODS OF PREPARATION THEREOF | MARTIN, PAUL C | 86d overdue |
| 18682951 | [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-7(8H)-ONE AS MITOCHONDRIAL PYRUVATE CARRIER INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GALSTER, SAMUEL LEONARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761626 | CELLULAR SUBSTITUTES AND METHODS OF PREPARATION THEREOF | MARTIN, PAUL C | 86d overdue |
| 18682951 | [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-7(8H)-ONE AS MITOCHONDRIAL PYRUVATE CARRIER INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682951 | [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-7(8H)-ONE AS MITOCHONDRIAL PYRUVATE CARRIER INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GALSTER, SAMUEL LEONARD | — | §102§103§112 | Non-Final OA | — | Pending | Feb 12, 2024 |
| 17761626 | CELLULAR SUBSTITUTES AND METHODS OF PREPARATION THEREOF | MARTIN, PAUL C | 1653 | §103§112 | Non-Final OA | 86d overdue | Pending | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial